ABSTRACT
Fibroblast
Growth Factor-2 (FGF2) is a major inducer of neovascularization (angiogenesis).
Heparin activates FGF2 by favoring formation of ternary complexes with
its cellular receptors (FGFRs).
Controlled
2-O-desulfation followed by exhaustive periodate oxidation/borohydride
reduction has been used to generate sulfation gaps within the prevalent
heparin sequences, building-up arrays of pentasulfated trisaccharides
(PST, consisting of a 2-O-sulfated iduronic acid flanked by two N,6-disulfated
glucosamines) spaced by reduced, glycol-split uronic acid (sU) residues.
The
structure of the prevalent sequences of the novel heparin derivative
has been confirmed by mono- and two-dimensional NMR analysis. NMR spin-lattice
relaxation times (T2) and Nuclear Overhauser effects suggest that the
sU residues act as flexible joints between the PST sequences and cause
a marked distortion of the chain conformation of heparin required for
formation of ternary complexes.
Since
the splitting reaction also occurs at the level of the essential glucuronic
acid residue of the active site for antithrombin, the heparin derivative
has no anticoagulant activity.
However,
it fully retains the FGF2-binding ability of the original heparin, as
shown by its capacity to protect FGF2 from trypsin cleavage and to prevent
the formation of heparan sulfate proteoglycan (HSPG)/FGF2/FGFR1 ternary
complexes. However, when compared to heparin it showed a reduced capacity
to induce FGF2 dimerization and to favor the interaction of 125I-FGF2
with FGFR1 in HSPG-deficient, FGFR1-transfected CHO cells. Accordingly,
it was more effective than heparin in inhibiting the mitogenic activity
exerted by FGF2 in cultured endothelial cells.
Finally,
it inhibited angiogenesis in a chick embrio chorioallantoic membrane
(CAM) assay in which heparin is inactive.
Biochemistry
(2002) 41, 10519-10528.